辉瑞（PFE）周二早盘下跌4%。尽管该公司第四季度仍超预期，但新冠产品销售额下降，并发布了保 守业绩指引，维持2026年预期不变。该公司同时通过Metsera交易强化其肥胖症药物管线。 责任编辑：张俊 SF065 辉瑞（PFE）周二早盘下跌4%。尽管该公司第四季度仍超预期，但新冠产品销售额下降，并发布了保 守业绩指引，维持2026年预期不变。该公司同时通过Metsera交易强化其肥胖症药物管线。 责任编辑：张俊 SF065 ...

【周六你需要知道的隔夜全球要闻：美联储新掌门再生变数，金属、美债应声下挫；特朗普关税案下周 或迎美最高法裁决】 1、特朗普周五表示，如果哈塞特不再当国家经济委员会主任，他的政府将失去最 有力的经济代言人之一，想让他继续留任。哈塞特一直被视为接替鲍威尔出任美联储主席的最热门人选 之一。 2、由于遴选下一任美联储主席的进程再添不确定性，金属全线下跌，现货黄金一度下跌1.7%， 现货白银一度下跌5.1%，LME期铜下跌2.3%，LME期铝下跌1.1%，LME期镍下跌5.3%，LME期锌下跌 3.2%，LME期锡下跌7.8%，LME期铅下跌2.6%。 3、随着市场加码押注凯文·沃什将获美联储主席提 名，美国国债价格下跌，交易员下调了对美联储2026年降息两次的预期。 4、交易员们评估伊朗紧张局 势以及更广泛市场的积极情绪，油价以小幅上涨结束动荡一周。WTI2月原油期货收于每桶59.44美元， 涨幅为0.42%；布伦特3月原油期货收于每桶64.13美元，涨幅为0.58%。 5、美国财长贝森特表示，美联 储主席候选人缩减至4人，预计美联储主席人选将在达沃斯之前或回来以后做决定。 6、特朗普称，可 能会对那些不支持美国获得 ...

Core Viewpoint - Fizer's acquisition of experimental obesity drugs positions the company as a credible competitor in the obesity treatment market, enhancing its growth potential and market presence [1][2]. Company Insights - Fizer's entry into the obesity market has been anticipated, with the potential to make a significant impact, especially with their once-monthly treatment options that differ from competitors like Lily and Novo [2][4]. - The oral peptide developed by Fizer does not require fasting, which could improve patient compliance compared to existing treatments [3]. - The obesity drug market is expected to be large enough to accommodate multiple competitors, suggesting that Fizer's new offerings could find a place alongside established players [4][6]. Market Dynamics - The obesity treatment market is projected to be driven by volume rather than price, with existing competitors facing pricing pressures [5]. - Fizer's once-monthly and oral treatment options may provide a competitive edge against established products from Lily and Novo [5]. - The infrastructure required for successful market entry includes a large sales force and complex contracts with payers, indicating significant investment needs for new entrants [7]. Investor Sentiment - Recent data from diabetes meetings has shifted investor sentiment positively towards Novo, highlighting a valuation disconnect between Novo and Lily, which may influence market dynamics [8][9]. - Investors are particularly interested in new trials, such as the Evoke trial examining oral simaglletide for Alzheimer's disease, indicating a broader interest in innovative treatments [9][10].

Core Viewpoint - Metsera, a startup focused on obesity drug development, saw its stock surge over 60% to a record high of $53.47 following Pfizer's agreement to acquire the company for approximately $4.9 billion, enhancing its research pipeline [1] Group 1: Acquisition Details - Pfizer will acquire Metsera for $47.50 per share in cash, with potential additional payments of up to $22.50 per share contingent on achieving three specific regulatory milestones [1] - The acquisition price represents a 43% premium over Metsera's closing price last Friday [1]